Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Engstrand

Psy112 - Factor Utilization Analysis of Extended Duration and Standard-Acting Recombinant Fviii Treatments for Severe Hemophilia a in Sweden

Value in Health

English

Related publications

Efficacy of Standard Prophylaxis Versus On-Demand Treatment With Bayer's Sucrose-Formulated Recombinant FVIII (rFVIII-FS) in Chinese Children With Severe Hemophilia A

Pediatric Hematology and Oncology

English

Pharmacokinetics and Pharmacodynamics of SCT800, a New Recombinant FVIII, in Hemophilia a Mice

Acta Pharmacologica Sinica

Medicine

Pharmacology

2016

English

Real-World Health Care Expenditure in Hemophilia a Patients Using Standard and Extended Half-Life Recombinant Factor VIII Products

English

Psy65 - Real-World Data Analysis of Us Claims Data on Coagulation Factor Ix Dispensation and Expenditures in Patients With Severe Hemophilia B: Standard Half-Life vs. Extended Half-Life Products

English

Aberrant Splicing and Premature Termination of Transcription of the FVIII Gene as a Cause of Severe Canine Hemophilia A: Similarities With the Intron 22 Inversion Mutation in Human Hemophilia

Thrombosis and Haemostasis

Hematology

2002

English

AMulticenter Clinical Study of Recombinant Factor VIII (BL-160) in Hemophilia a Patients

Japanese Journal of Thrombosis and Hemostasis

1993

English

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

English

Successful Management Preventing Severe Bleeding During the Perioperative Period for Subdural Hematoma by Using Recombinant Activated Coagulation Factor VII in a Case of Acquired Hemophilia A

Kitakanto Medical Journal

Medicine

2016

English

Perioperative Management of Hemophilia a Using Recombinant Factor VIII in Patients Undergoing Major or Minor Surgery

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Engstrand

Psy112 - Factor Utilization Analysis of Extended Duration and Standard-Acting Recombinant Fviii Treatments for Severe Hemophilia a in Sweden

Related publications

Efficacy of Standard Prophylaxis Versus On-Demand Treatment With Bayer's Sucrose-Formulated Recombinant FVIII (rFVIII-FS) in Chinese Children With Severe Hemophilia A

Pharmacokinetics and Pharmacodynamics of SCT800, a New Recombinant FVIII, in Hemophilia a Mice

Real-World Health Care Expenditure in Hemophilia a Patients Using Standard and Extended Half-Life Recombinant Factor VIII Products

Psy65 - Real-World Data Analysis of Us Claims Data on Coagulation Factor Ix Dispensation and Expenditures in Patients With Severe Hemophilia B: Standard Half-Life vs. Extended Half-Life Products

Aberrant Splicing and Premature Termination of Transcription of the FVIII Gene as a Cause of Severe Canine Hemophilia A: Similarities With the Intron 22 Inversion Mutation in Human Hemophilia

AMulticenter Clinical Study of Recombinant Factor VIII (BL-160) in Hemophilia a Patients

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

Successful Management Preventing Severe Bleeding During the Perioperative Period for Subdural Hematoma by Using Recombinant Activated Coagulation Factor VII in a Case of Acquired Hemophilia A

Perioperative Management of Hemophilia a Using Recombinant Factor VIII in Patients Undergoing Major or Minor Surgery